4. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
Findlay, J.M.#, Castro-Giner, F.#, Makino, S.#, Rayner, E.#, Kartsonaki, C., Cross, W., Kovac, M., Ulahannan, D., Palles, C., Gillies, R.S., MacGregor, T.P., Church, D., Maynard, N.D., Buffa, F., Cazier, J.-B., Graham, T.A., Wang, L.-M., Sharma, R.A., Middleton, M. & Tomlinson, I.*
University of Oxford, Churchill Hospital, Oxford Institute for Radiation Oncology, Queen Mary University of London, University of Birmingham, John Radcliffe Hospital, Oxford NIHR Comprehensive Biomedical Research Centre.
6. Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next Generation Sequencing
Nowak, J., Yurgelun, M., L. Bruce, J., Rojas-Rudilla, V., L. Hall, D., Shivdasani, P., P. Garcia, E., T. Agoston, A., Srivastava, A., Ogino, S., C. Kuo, F., I. Lindeman, N. & Dong, F.*
Harvard Medical School, the Center for Medical Genetics and Prevention, the Department of Medical Oncology, Harvard T.H.
Chan School of Public Health.
7. Microsatellite instability in prostate cancer by PCR or next-generation sequencing
Hempelmann, J., Lockwood, C., Konnick, E., Schweizer, M., Antonarakis, E., L. Lotan, T., Montgomery, B., S. Nelson, P., Klemfuss, N., J. Salipante, S. & C. Pritchard, C.*
University of Washington, Johns Hopkins University School of Medicine, VA Puget Sound Health Care System, Fred Hutchinson Cancer Research Center.
8.Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer
Lote, H.#, Spiteri, I.#, Ermini, L.#, Vatsiou, A., Roy, A., McDonald, A., Maka, N., Balsitis, M., Bose, N., Simbolo, M., Mafficini, A., Lampis, A., Hahne, J., Trevisani, F., Eltahir, Z., Mentrasti, G., Findlay, C., Kalkman, E.A.J., Punta, M.* & Valeri, N.*
The Institute of Cancer Research, The Royal Marsden NHS Trust, The Institute of Cancer Research, Crosshouse Hospital, Beatson West of Scotland Cancer Centre, Southern General Hospital, Crosshouse Hospital, ARC-NET Research Centre University of Verona, University of California San Francisco, Department of Psychology, Arizona State University, The Institute of Cancer Research, University of Padua.
9.The value of cell-free DNA for molecular pathology
Stewart, C., Kothari, P., Mouliere, F., Mair, R., Somnay, S., Benayed, R., Zehir, A., Weigelt, B., Dawson, S.-J., E Arcila, M., F Berger, M. & Wy Tsui, D.*
Memorial Sloan Kettering Cancer Center, University of Cambridge, Cancer Research UK Cambridge Institute, Memorial Sloan Kettering Cancer Center, Peter MacCallum Cancer Centre, University of Melbourne.
10. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I, Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications
Marginean, C.* & Melosky, B.
University of Ottawa, University of British Columbia.
12.Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma
M Javier, B., Yaeger, R., Wang, L., Sánchez-Vega, F., Zehir, A., Middha, S., Sadowska, J., Vakiani, E., Shia, J., Klimstra, D., Ladanyi, M., A Iacobuzio-Donahue, C. & F Hechtman, J.*
13.Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF
F Hechtman, J.*, Zehir, A., D Yaeger, R., Wang, L., Middha, S., Zheng, T., Hyman, D., Solit, D., E Arcila, M., Borsu, L., Shia, J., Vakiani, E., Saltz, L. & Ladanyi, M.